|Target||GM-CSF receptor alpha chain|
|Chemical and physical data|
|Molar mass||143.2 kg/mol g·mol−1|
|(what is this?)|
Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).
Mavrilimumab has been studied in a phase 1 dose-ranging trial and a phase 2a clinical trial, both sponsored by Medimmune. The phase 2a trial, which studied mavrilimumab doses of up to 100 mg, reported that 55.7% of subjects met the primary endpoint of a ≥1.2 decrease from baseline in disease activity scores at week 12 (vs. only 34.7% of placebo subjects).
As of 2013, two further clinical studies were reported to be underway in rheumatoid arthritis patients to investigate these effects further.
In early 2017 the phase IIb study was reported to be showing promising results.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab" (PDF). American Medical Association.
- Gerd R Burmester; Eugen Feist; Matthew A Sleeman; Bing Wang; Barbara White; Fabio Magrini (1 September 2011). "Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study". Ann. Rheum. Dis. 70 (9): 1542–1549. doi:10.1136/ard.2010.146225. PMC 3147227. PMID 21613310.
- "Archived copy" (PDF). Archived from the original (PDF) on 2012-09-28. Retrieved 2011-09-08.CS1 maint: archived copy as title (link)
- Gerd R Burmester; Michael E Weinblatt; Iain B McInnes; Duncan Porter; Olga Barbarash; Mykola Vatutin; Istvan Szombati; Ehsanollah Esfandiari; Matthew A Sleeman; Christopher D Kane; Guy Cavet; Bing Wang; Alex Godwood; Fabio Magrini & the EARTH Study Group (2013). "Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis". Ann Rheum Dis. 72 (9): 1445–1452. doi:10.1136/annrheumdis-2012-202450. PMC 3756523. PMID 23234647.
- Manuela Di Franco; Maria Chiara Gerardi; Bruno Lucchino & Fabrizio Conti (12 March 2014). "Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis". Core Evidence. 9: 41–48. doi:10.2147/CE.S39770. PMC 3958547. PMID 24648832.
- Agent that Targets GM-CSF Shows Promise in RA - Novel monoclonal antibody was rapidly effective in mild-to-moderate disease. Feb 2017
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|